Authors: Ni Luh Putu Diah Fitriyani1, Gretta Niken Purbosari1, Suharjono2,
1Master of Clinical Pharmacy, 2Department Of Clinical Pharmacy,
Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia
Email: shj_ms_id@yahoo.co.id & nlpdiaf@gmail.com
Abstract
Hyperphosphatemia is a disorder of mineral metabolism in chronic kidney disease that caused by decreased kidney ability to excrete phosphate. It is potentially life threatening by contributed to the development of mineral bone disease and cardiovascular calcification. Those complications prevented by diet restriction, used of phosphate binders and hemodialysis and must be done simultaneously to be able to control normal phosphate levels, thus risk of morbidity and mortality can be decreased. Oral phosphate binders is used to inhibit absorption of phosphate in gastrointestinal, which derived from phosphate intake. The currently available oral phosphate binding agents have their respective deficiencies and none of them have become superior among others inspite of a progressive development of phosphate binding agents. Effectiveness of these agents which is associated with phosphate binding capacity, depends on pH in gastrointestinal. Therefore, these agents should be used at the right time.
Keywords: Oral Phosphate Binders, Hyperphosphatemia, Chronic Kidney Disease
